Status:
COMPLETED
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
Lead Sponsor:
Hospital de Clinicas José de San Martín
Collaborating Sponsors:
SILVATEAM
Conditions:
Irritable Bowel Syndrome
Diarrhea
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Irritable bowel syndrome is a highly prevalent disorder and consumes many health resources. Its physiopathogenesis is multifactorial. Some of the factors involved have to do with the alteration of the...
Detailed Description
In vitro studies have shown that chestnut and quebracho extract has a prebiotic effect of modulating the intestinal microbiota, but also, bacterial fermentation produces metabolites with powerful anti...
Eligibility Criteria
Inclusion
- IBS patients: Both sexes with a diagnosis of irritable bowel syndrome variety diarrhea according to the Rome IV criteria
- Healthy Controls: Relatives of patients who do not show any disease, who do not take medication or present symptoms.
Exclusion
- patients with digestive tract disease,
- systemic diseases such as severe heart, kidney or liver failure,
- history of previously known digestive tract surgeries and / or intestinal adhesions,
- diabetes mellitus,
- cirrhosis,
- inflammatory bowel disease,
- celiac disease,
- patients with cognitive impairment,
- alcoholics,
- lack of consent .
- patients who have received antibiotics in the last month.
Key Trial Info
Start Date :
September 21 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 20 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05207618
Start Date
September 21 2021
End Date
April 20 2022
Last Update
July 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Clinicas Jose de San Martin. Buenos Aires University
Buenos Aires, Argentina, B1622